Rob Finizio

Rob Finizio is a successful entrepreneur with over 30 years of experience building public and private companies in the pharmaceutical and medical device industries. Rob co-founded CareFusion in 2001, the market leader in medication patient safety, and sold CareFusion to Cardinal Health (CAH) in 2006. Cardinal Health spun CareFusion out in 2009 (CFN) with a listing on the S&P 500.

After CareFusion, Rob co-founded TherapeuticsMD (TXMD) in 2008. As the CEO and Vice Chairman, Rob developed TXMD from a start-up to the Women’s Health Pharmaceutical market leader in drug development proudly the first and only Women’s Health company to have 3 new drugs approved in a single year (2018). In 2011, Rob took TXMD public on the NYSE and achieved a market capitalization of well over a billion dollars. Since inception, Rob raised more than $1 Billion in private / public equity and debt.

Currently, Rob is an Executive Director at Pleo Pharma and General Partner with MintPharma Capital, an early-stage BioTech venture capital fund that invests in early-stage Biotech companies that are developing solutions for indications where no FDA approved product currently exists.

Rob sits on the Board of Directors for PleoPharma, Myosin Therapeutics, Vycellix, NOXX Therapeutics, ICaPath and Vycellix. He is the Chairman Emeritus of Bio-Florida and a Board Member for the Palm Beach County Sheriff’s Office Foundation. Prior to his healthcare career, Rob graduated from the University of Miami with a Bachelor of Arts degree studying Premed and Psychology and taught English in Osaka, Japan after graduation.

Rob has appeared multiple times on CNBC’s Mad Money, Squawk Box and Bloomberg has been a speaker at Harvard’s Business School’s Healthcare Alumni Association and at the University of Miami’s LaunchPad for Entrepreneurs. In addition, Rob’s companies have been awarded the Deloitte Fast 500 multiple times recognizing the 500 fastest revenue growing companies in the United States.